Loxo Oncology Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
-
-
21,300.00
Cost of Goods Sold (COGS) incl. D&A
-
30.00
17.00
77.00
-
Gross Income
-
30.00
17.00
77.00
-
SG&A Expense
10,290.00
20,660.00
36,058.00
72,901.00
133,571.00
EBIT
10,290.00
20,690.00
36,075.00
72,978.00
112,396.00
Unusual Expense
-
-
-
200.00
40,000.00
Pretax Income
10,290.00
20,672.00
35,876.00
72,398.00
148,876.00
Consolidated Net Income
10,302.00
20,672.00
35,876.00
72,398.00
148,876.00
Net Income
10,302.00
20,672.00
35,876.00
72,398.00
148,876.00
Net Income After Extraordinaries
10,302.00
20,672.00
35,876.00
72,398.00
148,876.00
Net Income Available to Common
10,302.00
20,706.00
35,876.00
72,398.00
148,876.00
EPS (Basic)
110.61
3.06
2.12
3.46
5.31
Basic Shares Outstanding
15,941.00
6,773.70
16,894.50
20,905.40
28,035.70
EPS (Diluted)
0.65
3.06
2.12
3.46
5.31
Diluted Shares Outstanding
15,941.00
6,773.70
16,894.50
20,905.40
28,035.70
EBITDA
10,290.00
20,660.00
36,058.00
72,901.00
112,271.00
Non-Operating Interest Income
-
18.00
199.00
780.00
3,520.00
Other After Tax Income (Expense)
12.00
-
-
-
-
Preferred Dividends
-
34.00
-
-
-
About Loxo Oncology
View Profile
